
Please try another search
By Michael Erman
(Reuters) - The U.S. National Institutes of Health is in talks with Pfizer Inc (NYSE:PFE) about studying whether a longer course of the drugmaker's COVID-19 antiviral treatment Paxlovid is needed to prevent reinfections, top U.S. infectious diseases expert Dr. Anthony Fauci said on Wednesday.
"We're going to be planning what studies we're going to be doing relatively soon, within the next few days" in order to determine whether or not a longer course is needed, Fauci said during a White House COVID-19 briefing.
Rising COVID-19 cases in the United States are driving up use of therapeutics, with more than 660,000 courses of Paxlovid pills administered in the country so far.
Some patients have reported that COVID symptoms recurred after completing the five-day course of treatment and experiencing improvement, but exactly how many have experienced such a rebound is unclear.
In Pfizer's clinical trial, around 2% of recipients who received the two-drug treatment saw an increase in viral load after completing the standard course, compared with around 1.5% of placebo recipients.
White House COVID-19 response coordinator Dr. Ashish Jha said that data was compiled when Delta was the dominant variant of the coronavirus, and it is unclear whether reinfections are more common with Omicron now predominant.
Jha said that reinfections do not seem to hamper Paxlovid's ability to reduce hospitalizations and deaths from COVID-19.
Pfizer has suggested that a second five-day course of Paxlovid could treat reinfections. The U.S. Food and Drug Administration said there is currently no evidence to support taking a second five-day course or a 10-day course of the pills.
(This story refiles to fix typographical error in third paragraph)
By Zhang Mengying Investing.com – Asia Pacific stocks were up on Monday morning after Wall Street rebounded strongly at the end of last week despite fears of prolonged inflation...
By Kevin Buckland and Sam Byford TOKYO (Reuters) - Stocks gained in Asia on Monday amid improved risk sentiment after Wall Street rebounded strongly at the end of last week as oil...
By Oliver Gray Investing.com - U.S. stock futures were trading lower during Sunday's evening deals, easing from a major rebound last week as investors monitored growing recession...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.